Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433757 | 0.81 | HPGD (0.57) | SLC6A4HPGDTSHRCCKARALDH1A1 | |
| SCHEMBL16450946 | 0.80 | TSHR (0.49) | SLC6A4HPGDTSHRALDH1A1HTT | |
| SCHEMBL11644999 | 0.80 | HPGD (0.56) | SLC6A4HPGDTSHRCCKARALDH1A1 | |
| SCHEMBL7980416 | 0.79 | L3MBTL1 (0.58) | HPGDTSHRMAPTPOLBHTT | |
| SCHEMBL2430064 | 0.78 | SLC6A4 (0.74) | SLC6A4HPGDMAPTSMN1; SMN2MEN1 | |
| SCHEMBL11645763 | 0.78 | SLC6A4 (0.67) | SLC6A4HPGDTSHRCCKARSMN1; SMN2 | |
| SCHEMBL7977632 | 0.75 | HPGD (0.50) | HPGDTSHRALDH1A1MAPTPOLB | |
| SCHEMBL7974489 | 0.74 | TSHR (0.43) | HPGDTSHRPOLBHTT | |
| SCHEMBL7964353 | 0.74 | TSHR (0.47) | HPGDTSHRMAPTSMN1; SMN2POLB | |
| SCHEMBL12327101 | 0.74 | TSHR (0.52) | HPGDTSHRPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010011302-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | SLC6A4 670/4885HPGD 40/4885TSHR 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.